open access

Vol 7, No 3 (2022)
Research paper
Published online: 2022-09-15
Get Citation

Screening role of complete blood cell count indices and C reactive protein in patients who are symptomatic for COVID-19

Bijan Ansari-Moghaddam1, Seyyed Amir Yasin Ahmadi2, Maryam Matouri3, Ali Ghaemmaghami4, Ali Amiri5, Elham Tavakkol6, Farhad Shahsavar1
·
Disaster Emerg Med J 2022;7(3):176-181.
Affiliations
  1. Department of Immunology, Lorestan University of Medical Sciences, Khorramabad, Iran
  2. Student Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran
  3. Immunology Department, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  4. ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, Hazrat Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
  5. Division of Pulmonology, Department of Internal Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
  6. Department of Radiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

open access

Vol 7, No 3 (2022)
ORIGINAL ARTICLES
Published online: 2022-09-15

Abstract

INTRODUCTION: Diagnosis of COVID-19 is through polymerase chain reaction (PCR) or typical involvement of the lung by the virus in computed tomography (CT) scan. However, PCR is not always available, and also CT scan has a high dose of radiation. This study was performed to find the role of complete blood cell (CBC) indices and qualitative C-reactive protein (CRP) in screening of symptomatic patients.
MATERIAL AND METHODS: A diagnostic accuracy study was performed on symptomatic cases in Abadan. Four stepwise logistic regression models were designed that the outcomes were PCR positivity, CT scan positivity, PCR and CT scan positivity, and COVID-19 positivity (i.e., PCR or CT scan positivity). Post-estimation receiver operating characteristics (ROC) curve analysis was performed to report the area under the curve (AUC).
RESULTS: A total of 104 patients were studied. The most accurate model was for the prediction of CT scan positivity (AUC = 0.874) in which the predictors were age [odds ratio (OR) =1.063] and CRP (OR = 2.661 for each plus of positivity). The second accurate model was for the prediction of COVID-19 positivity (AUC = 0.828) in which the predictors were white blood cell count (OR = 0.735 for every 1000 counts per μL) and neutrophil per lymphocyte ratio (OR = 1.248).
CONCLUSIONS: Higher levels of CRP are associated with and predictor of lung involvement in COVID-19 infection. CRP qualitative levels can be measured before a CT scan if there is no other indication for imaging.

Abstract

INTRODUCTION: Diagnosis of COVID-19 is through polymerase chain reaction (PCR) or typical involvement of the lung by the virus in computed tomography (CT) scan. However, PCR is not always available, and also CT scan has a high dose of radiation. This study was performed to find the role of complete blood cell (CBC) indices and qualitative C-reactive protein (CRP) in screening of symptomatic patients.
MATERIAL AND METHODS: A diagnostic accuracy study was performed on symptomatic cases in Abadan. Four stepwise logistic regression models were designed that the outcomes were PCR positivity, CT scan positivity, PCR and CT scan positivity, and COVID-19 positivity (i.e., PCR or CT scan positivity). Post-estimation receiver operating characteristics (ROC) curve analysis was performed to report the area under the curve (AUC).
RESULTS: A total of 104 patients were studied. The most accurate model was for the prediction of CT scan positivity (AUC = 0.874) in which the predictors were age [odds ratio (OR) =1.063] and CRP (OR = 2.661 for each plus of positivity). The second accurate model was for the prediction of COVID-19 positivity (AUC = 0.828) in which the predictors were white blood cell count (OR = 0.735 for every 1000 counts per μL) and neutrophil per lymphocyte ratio (OR = 1.248).
CONCLUSIONS: Higher levels of CRP are associated with and predictor of lung involvement in COVID-19 infection. CRP qualitative levels can be measured before a CT scan if there is no other indication for imaging.

Get Citation

Keywords

COVID-19; C-reactive protein; CT scan; clinical reasoning; statistical modeling

About this article
Title

Screening role of complete blood cell count indices and C reactive protein in patients who are symptomatic for COVID-19

Journal

Disaster and Emergency Medicine Journal

Issue

Vol 7, No 3 (2022)

Article type

Research paper

Pages

176-181

Published online

2022-09-15

Page views

6981

Article views/downloads

247

DOI

10.5603/DEMJ.a2022.0028

Bibliographic record

Disaster Emerg Med J 2022;7(3):176-181.

Keywords

COVID-19
C-reactive protein
CT scan
clinical reasoning
statistical modeling

Authors

Bijan Ansari-Moghaddam
Seyyed Amir Yasin Ahmadi
Maryam Matouri
Ali Ghaemmaghami
Ali Amiri
Elham Tavakkol
Farhad Shahsavar

References (16)
  1. Zhang M, Xiao E, Liu J, et al. An emerging marker predicting the severity of COVID-19: neutrophil-lymphocyte count ratio. .
  2. Wu J, Wu X, Zeng W, et al. Chest CT findings in patients with coronavirus disease 2019 and its relationship with clinical features. Invest Radiol. 2020; 55(5): 257–261.
  3. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020; 58(7): 1131–1134.
  4. Xia W, Shao J, Guo Yu, et al. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. Pediatr Pulmonol. 2020; 55(5): 1169–1174.
  5. Tan C, Huang Y, Shi F, et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J Med Virol. 2020; 92(7): 856–862.
  6. Poggiali E, Zaino D, Immovilli P, et al. Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients. Clin Chim Acta. 2020; 509: 135–138.
  7. Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020; 50(4): 332–334.
  8. Li D, Wang D, Dong J, et al. False-Negative results of real-time reverse-transcriptase polymerase chain reaction for severe acute respiratory syndrome coronavirus 2: role of deep-learning-based CT diagnosis and insights from two cases. Korean J Radiol. 2020; 21(4): 505–508.
  9. Hao W, Li M. Clinical diagnostic value of CT imaging in COVID-19 with multiple negative RT-PCR testing. Travel Med Infect Dis. 2020; 34: 101627.
  10. Caruso D, Pucciarelli F, Zerunian M, et al. Chest CT features of COVID-19 in Rome, Italy. Radiology. 2020; 296(2): E79–E85.
  11. Wang F, Nie J, Wang H, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. 2020; 221(11): 1762–1769.
  12. Wang G, Wu C, Zhang Q, et al. C-Reactive protein level may predict the risk of COVID-19 aggravation. Open Forum Infect Dis. 2020; 7(5): ofaa153.
  13. Mardani R, Ahmadi Vasmehjani A, Zali F, et al. Laboratory parameters in detection of COVID-19 patients with positive RT-PCR; a diagnostic accuracy study. Arch Acad Emerg Med. 2020; 8(1): e43.
  14. Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020; 127: 104370.
  15. Fu J, Kong J, Wang W, et al. The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China. Thromb Res. 2020; 192: 3–8.
  16. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020; 34: 101623.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl